Latest:
Dr. Chauncey on Isatuximab Combinations in Multiple Myeloma
Thomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Samantha A. Armstrong, MD
Samantha A. Armstrong, MD, is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health
Latest:
Urothelial ESMO 2025 Updates
OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.
Fay Kastrinos, MD, MPH
Latest:
Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive Considerations
In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.
Meghan K. Berkenstock, MD
Latest:
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.
Gary Doherty, MRCP, PhD, Cambridge University Hospitals NHS Foundation Trust
Latest:
EGFR+ NSCLC: Advice for Community Oncologists
A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Jaume Capdevila, MD, PhD
Latest:
Efficacy and Safety of the DLL3/CD3 T-Cell Engager Obrixtamig in Patients With Extrapulmonary Neuroendocrine Carcinomas With High or Low DLL3 Expression: Results From an Ongoing Phase 1 Trial
Jaume Capdevila, MD, PhD, presents results from a phase 1 study showing that obrixtamig monotherapy achieves a 40% response rate and durable disease control with manageable safety in patients with extrapulmonary neuroendocrine carcinoma, particularly those with high DLL3 expression.
Panagiotis J. Vlachostergios, MD, PhD
Latest:
Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape
Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.
Manmeet S. Ahluwalia, MD, MBA, FASCO
Manmeet S. Ahluwalia, MD, MBA, FASCO, is the deputy pirector, chief scientific officer, chief of medical oncology, and Fernandez Family Foundation Endowed Chair in Cancer Research at Miami Cancer Institute, which is part of Baptist Health South Florida.
Latest:
Dr Ahluwalia on the Evolution of Precision Medicine in Oncology
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.
David D'Ambrosio, MD
Latest:
Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer
David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.